Evaluation of efficacy of anti-allergic ophthalmic solution for allergic conjunctival diseases using the allergic conjunctival disease medical treatment assessment system.

Evaluation of efficacy of anti-allergic ophthalmic solution for allergic conjunctival diseases using the allergic conjunctival disease medical treatment assessment system. - Evaluation of efficacy of anti-allergic ophthalmic solution for allergic conjunctival diseases.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013173

Enrollment

Registered

2014-02-16

Start date

2014-02-16

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic conjunctival diseases

Interventions

Epinastine hydrochloride ophthalmic solution Sodium cromoglicate ophthalmic solution

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with allergic conjunctival diseases 1) Male or female of age of 4 years or older. 2) Patients who provided written informed consent for participating in this study. 3) Patients who are diagnosed as allergic conjunctival diseases according to the guideline for allergic conjunctival diseases in Japan.

Exclusion criteria

Exclusion criteria: 1) Patients with anterior segment disease (including blepharitis, lagophthalmos, blepharospasm, iritis and conjunctivochalasis) other than allergic conjunctival diseases at the study initiation. 2) Patients who cannot discontinue eye drops (include all eye drops such as prescribed drug and OTC medicine) except for the study drug or the control drug from the study initiation until the end of study treatment or who expect to use those drugs 3) Patients with a history of surgery of the ocular surface within 12 months or patients with a history of intraocular surgery within three months prior to the study drug initiation examination. 4) Patients who have difficulty in sampling. 5) Patients that a study supervisor or a study partaker judged participation in this study to be inappropriate

Design outcomes

Primary

Measure	Time frame
Comparative study on therapeutic efficacy of anti-allergic ophthalmic solution for allergic conjunctival diseases using allergic conjunctival diseases therapeutic assessment system.	—

Secondary

Measure	Time frame
Investigation of useful biomarker in tears or ocular surface for allergic conjunctival disease practice by the comparison between objective finding and ocular surface clinical examination.	—

Countries

Japan

Contacts

Public ContactJun Shoji

Nihon University School of Medicine Division of Ophthalmology, Department of Visual Sciences

shojig3589eye@athena.ocn.ne.jp03-3972-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026